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Articles

Diarrhoeal disease and subsequent risk of death in infants
and children residing in low-income and middle-income
countries: analysis of the GEMS case-control study and
12-month GEMS-1A follow-on study
Myron M Levine, Dilruba Nasrin, Sozinho Acácio, Quique Bassat, Helen Powell, Sharon M Tennant, Samba O Sow, Dipika Sur, Anita K M Zaidi,
Abu S G Faruque, M Jahangir Hossain, Pedro L Alonso, Robert F Breiman, Ciara E O’Reilly, Eric D Mintz, Richard Omore, John B Ochieng,
Joseph O Oundo, Boubou Tamboura, Doh Sanogo, Uma Onwuchekwa, Byomkesh Manna, Thandavarayan Ramamurthy, Suman Kanungo,
Shahnawaz Ahmed, Shahida Qureshi, Farheen Quadri, Anowar Hossain, Sumon K Das, Martin Antonio, Debasish Saha, Inacio Mandomando,
William C Blackwelder, Tamer Farag, Yukun Wu, Eric R Houpt, Jaco J Verweiij, Halvor Sommerfelt, James P Nataro, Roy M Robins-Browne,
Karen L Kotloff

Summary

Background The Global Enteric Multicenter Study (GEMS) was a 3-year case-control study that measured the burden,
aetiology, and consequences of moderate-to-severe diarrhoea (MSD) in children aged 0–59 months. GEMS-1A,
a 12-month follow-on study, comprised two parallel case-control studies, one assessing MSD and the other less-severe
diarrhoea (LSD). In this report, we analyse the risk of death with each diarrhoea type and the specific pathogens
associated with fatal outcomes.
Methods GEMS was a prospective, age-stratified, matched case-control study done at seven sites in Africa and
Asia. Children aged 0–59 months with MSD seeking care at sentinel health centres were recruited along with one
to three randomly selected matched community control children without diarrhoea. In the 12-month GEMS-1A
follow-on study, children with LSD and matched controls, in addition to children with MSD and matched controls,
were recruited at six of the seven sites; only cases of MSD and controls were enrolled at the seventh site. We
compared risk of death during the period between enrolment and one follow-up household visit done about
60 days later (range 50–90 days) in children with MSD and LSD and in their respective controls. Approximately
50 pathogens were detected using, as appropriate, classic bacteriology, immunoassays, gel-based PCR and
reverse transcriptase PCR, and quantitative real-time PCR (qPCR). Specimens from a subset of GEMS cases
and controls were also tested by a TaqMan Array Card that compartmentalised probe-based qPCR for
32 enteropathogens.
Findings 223 (2·0%) of 11 108 children with MSD and 43 (0·3%) of 16 369 matched controls died between study
enrolment and the follow-up visit at about 60 days (hazard ratio [HR] 8·16, 95% CI 5·69–11·68, p<0·0001). 12 (0·4%)
of 2962 children with LSD and seven (0·2%) of 4074 matched controls died during the follow-up period (HR 2·78,
95% CI 0·95–8·11, p=0·061). Risk of death was lower in children with dysenteric MSD than in children with nondysenteric MSD (HR 0·20, 95% CI 0·05–0·87, p=0·032), and lower in children with LSD than in those with nondysenteric MSD (HR 0·29, 0·14–0·59, p=0·0006). In children younger than 24 months with MSD, infection with
typical enteropathogenic Escherichia coli, enterotoxigenic E coli encoding heat-stable toxin, enteroaggregative E coli,
Shigella spp (non-dysentery cases), Aeromonas spp, Cryptosporidium spp, and Entamoeba histolytica increased risk of
death. Of 61 deaths in children aged 12–59 months with non-dysenteric MSD, 31 occurred among 942 children qPCRpositive for Shigella spp and 30 deaths occurred in 1384 qPCR-negative children (HR 2·2, 95% CI 1·2–3·9, p=0·0090),
showing that Shigella was strongly associated with increased risk of death.
Interpretation Risk of death is increased following MSD and, to a lesser extent, LSD. Considering there are
approximately three times more cases of LSD than MSD in the population, more deaths are expected among children
with LSD than in those with MSD. Because the major attributable LSD-associated and MSD-associated pathogens are
the same, implementing vaccines and rapid diagnosis and treatment interventions against these major pathogens are
rational investments.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license.

www.thelancet.com/lancetgh Vol 8 February 2020

Lancet Glob Health 2020;
8: e204–14
Published Online
December 18, 2019
https://doi.org/10.1016/
S2214-109X(19)30541-8
See Comment page e157
Center for Vaccine
Development and Global
Health (Prof M M Levine MD,
D Nasrin PhD, H Powell PhD,
S M Tennant PhD,
Prof W C Blackwelder PhD,
T Farag PhD, Y Wu PhD,
Prof J P Nataro MD,
Prof K L Kotloff MD),
Department of Medicine
(Prof M M Levine, D Nasrin,
S M Tennant,
Prof W C Blackwelder, T Farag,
Y Wu, Prof J P Nataro,
Prof K L Kotloff), and
Department of Pediatrics
(Prof M M Levine, Prof J P Nataro,
Prof K L Kotloff), University of
Maryland School of Medicine,
Baltimore, MD, USA; Centro de
Investigação em Saúde da
Manhiça, Maputo,
Mozambique (S Acácio MD,
Prof Q Bassat MD,
Prof P L Alonso MD,
I Mandomando PhD); Instituto
Nacional de Saúde, Ministério
de Saúde, Maputo,
Mozambique (S Acácio,
I Mandomando); ISGlobal,
Hospital Clínic—Universitat de
Barcelona, Barcelona, Spain
(Prof Q Bassat, Prof P L Alonso);
Institució Catalana de Recerca i
Estudis Avançats (ICREA),
Barcelona, Spain
(Prof Q Bassat); Pediatric
Infectious Diseases Unit,
Pediatrics Department,
Hospital Sant Joan de Déu
(University of Barcelona),
Barcelona, Spain

e204

Articles

(Prof Q Bassat); Consorcio de
Investigación Biomédíca en
Red de Epidemiología y Salud
Pública (CIBERESP), Madrid,
Spain (Prof Q Bassat); Centre
pour le Développement des
Vaccins, Bamako, Mali
(Prof S O Sow MD,
B Tamboura PharmD,
D Sanogo MD,
U Onwuchekwa MS); National
Institute of Cholera and Enteric
Diseases, Kolkata, India
(D Sur MD, B Manna PhD,
T Ramamurthy PhD,
S Kanungo MBBS) Department
of Paediatrics and Child Health,
Aga Khan University, Karachi,
Pakistan (Prof A K M Zaidi MBBS,
S Qureshi MSc, F Quadri MBBS);
Bill & Melinda Gates
Foundation, Seattle, WA, USA
(Prof A K M Zaidi); International
Centre for Diarrhoeal Disease
Research, Mohakhali, Dhaka,
Bangladesh (A S G Faruque MD,
S Ahmed MBBS, A Hossain MD,
S K Das MBBS); Medical
Research Council Unit
The Gambia at the London
School of Hygiene and Tropical
Medicine, Banjul, The Gambia
(M J Hossain MBBS,
M Antonio PhD, D Saha MBBS);
Global Malaria Programme,
World Health Organization,
Geneva, Switzerland
(Prof P L Alonso); Kenya Medical
Research Institute/Centers for
Disease Control and
Prevention, Kisumu, Kenya
(Prof R F Breiman MD,
R Omore PhD, J B Ochieng MSc,
J O Oundo PhD); Global Disease
Detection Division, Kenya
Office of the US Centers for
Disease Control and
Prevention, Nairobi, Kenya
(Prof R F Breiman); Global
Health Institute, Emory
University, Atlanta, GA, USA
(Prof R F Breiman); Division of
Foodborne, Waterborne and
Environmental Diseases,
Centers for Disease Control and
Prevention, Atlanta, GA, USA
(C E O’Reilly PhD, E D Mintz MD);
Centers for Disease Control and
Prevention Country Office,
Addis Ababa, Ethiopia
(C E O’Reilly); London School of
Hygiene and Tropical Medicine,
Harar, Ethiopia (J O Oundo);
Translational Health Science
and Technology Institute,
Faridabad, India
(T Ramamurthy); PPD,
San Diego, CA, USA (F Quadri);
Square Hospitals, Mohakhali,
Dhaka, Bangladesh (A Hossain);
Menzies School of Health

e205

Research in context
Evidence before this study
Although diarrhoeal-associated deaths have steadily decreased
during the past two decades, diarrhoeal diseases remain
responsible for an estimated 9% of all mortality in children
younger than 5 years, accounting for about 499 000 to
525 000 annual deaths. Accurate descriptions of the major
causative pathogens, determinants, and risk factors for these
deaths are necessary to design improved preventive and
therapeutic strategies that will have maximal impact on diarrhoeal
disease, and thus, on young child survival. We searched PubMed
for articles published in English, Spanish, French, or Portuguese
between Jan 1, 2000, and Sept 30, 2019, using the terms “low
and middle-income countries” or “developing countries” AND
“diarrheal deaths” OR “diarrhea AND mortality”. We included
earlier reports, and articles identified in reference lists, as
appropriate. Previous aetiological studies have put the focus on
specific pathogens in particular high-risk populations, including,
among others, rotavirus, diarrhoeagenic Escherichia coli, or
Shigella spp. However, few studies have included comprehensive
investigation of a representative sample of diarrhoea cases in
children in different low-income regions of the world where
diarrhoeal illness remains a major public health problem.
Added value of this study
Data from the GEMS study showed that during the
approximately 60-day follow-up period, children with MSD had
an 8·5 times increased risk of death compared with control

Introduction
The fourth Millennium Development Goal (MDG4),
which aimed to reduce mortality in children younger
than 5 years by two-thirds by 2015 compared with the
1990 baseline, triggered efforts to improve monitoring
and to identify the predominant causes of paediatric
deaths.1,2 Although in 1990 south Asia’s enormous annual
birth cohort contributed the largest number of deaths
in children younger than 5 years (4·78 million vs
3·77 million for sub-Saharan Africa), the highest under-5
mortality was reported in sub-Saharan Africa (177 per
1000 livebirths vs 126 per 1000 livebirths in south Asia).1,2
To achieve MDG4, the major causes of under-5 mortality
in these two geographical regions had to be reduced
substantially. Early estimates identified diarrhoeal disease
as the second most common cause of under-5 mortality
after pneumonia, accounting for approximately 19% of
deaths.1,3 Subsequent analyses indicated that under-5
mortality was falling globally, including the proportion
of post-neonatal child mortality (age 1–59 months)
attributable to diarrhoeal disease.4–6
One post-2015 challenge is to accelerate the decrease
in mortality from diarrhoeal disease so that by 2030
the overall under-5 mortality will not exceed 25 per
1000 livebirths in any country worldwide (part of
Sustainable Development Goal [SDG] 3.2).7 Improved
treatment of diarrhoeal disease, water and sanitation

children without diarrhoea. The GEMS-1A study corroborates
the MSD risk of death (nearly 12 times increase in cases
compared with controls) and further showed that children with
LSD had a 2·8 times increased risk of death compared with
controls, although this difference was not statistically
significant. Somewhat surprisingly, children with nondysenteric MSD had a substantially higher risk of dying than did
children with dysenteric MSD; notably, most children with
dysentery in the GEMS and GEMS-1A studies received antiShigella antibiotics in accordance with WHO standard of care
recommendations. About half the deaths in children aged
12–59 months with non-dysenteric MSD were positive for
Shigella spp when quantitative real-time PCR (qPCR) testing was
performed. Notably, three-quarters of the qPCR-positive fatal
non-dysenteric MSD cases had negative cultures for Shigella spp.
Implications of all the available evidence
Collectively, these observations provide a strong rationale for
vigorously acting upon all severities of diarrhoeal illness.
Additionally, the prominence of delayed deaths occurring 14 or
more days after enrolment of cases calls for a need to ensure
follow-up for several weeks beyond the initial management of
the acute diarrhoeal episode. The main pathogens implicated in
MSD-associated or LSD-associated deaths were found to be the
same, thus supporting the need to pursue common preventive
and therapeutic strategies for diarrhoea as a major threat to
child survival.

upgrades, and development and introduction of vaccines
against major diarrhoeal disease agents associated with
fatality could achieve this ambitious aim. Diarrhoeal
mortality estimates from the 2016 Global Burden of
Disease Study8 suggest that this goal is feasible, including
in sub-Saharan Africa.8,9
The Global Enteric Multicenter Study (GEMS) was
done in the first decade of the millennium when
diarrhoeal disease constituted the second most frequent
cause of under-5 mortality and there was uncertainty
regarding the relative mortality contribution of specific
enteric pathogens.10–12 During the last quarter of the 20th
century, many new diarrhoeal pathogens were identified
and improved diagnostics in the first decades of the 21st
century offered high-throughput options with increased
sensitivity to detect these pathogens in individuals with
diarrhoeal disease and in controls without diarrhoea.10
The 3-year GEMS case-control study identified aetio
logical agents associated with moderate-to-severe diarrhoea
(MSD), assuming that cases of this severity might be fatal
if the patient could not access health care.11 Children
with MSD were enrolled at sentinel health centres that
served demographically monitored populations so that
pathogen-specific population-based incidence rates could
be estimated.12–14 Matched controls without diarrhoea were
selected among children in the community. The study
reported adjusted attributable fractions for pathogens that
www.thelancet.com/lancetgh Vol 8 February 2020
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took into account the presence of enteropathogens in
matched controls without diarrhoeal disease and adjusted
for the presence of multiple pathogens.12–15 The GEMS
study included a single household visit about 60 days after
enrolment to ascertain the vital status of children with
MSD and controls, and to assess linear growth since
enrolment.12,13 Thus, deaths that occurred among cases and
controls during a prospective 60-day period were captured.
The GEMS study identified four major pathogens
associated with MSD (rotavirus, Cryptosporidium spp,
enterotoxigenic Escherichia coli encoding heat-stable toxin
[ST-ETEC] with or without co-expression of heat-labile
enterotoxin, and Shigella spp) and showed that children
with MSD had more linear growth faltering during the
follow-up period than did controls.12 The GEMS study also
showed that during the approximately 60-day follow-up
period, MSD was associated with an 8·5 times increase
in the odds of death compared with no diarrhoea.12
Many deaths in children with MSD occurred at home
beyond the first week post-enrolment and would have
been missed were it not for the 60-day visit to case and
control households.
Children with MSD in the GEMS study accounted for
only 24·1% of all children with diarrhoeal disease who
presented to the sentinel health centres; no data were
obtained from children seeking health care who had the
more common less-severe diarrhoea (LSD) and who
were therefore ineligible for enrolment into the GEMS
study. Accordingly, a 1-year follow-on study, GEMS-1A,
was done, consisting of two parallel case-control studies,
one enrolling cases of MSD and matched controls and
the other enrolling cases of LSD and matched controls.16
The GEMS-1A study assessed the overall and pathogenspecific, population-based, attributable incidence and the
pathogen-specific attributable fraction, and the frequency
of nutritional faltering in children with the two diarrhoeal
syndromes. Outcomes were assessed by site and age
stratum, and across all sites for incidence and nutritional
outcomes. Because dysentery was an exclusion criterion
for LSD, in the GEMS-1A study a non-dysentery MSD
category was included to compare watery diarrhoea
syndromes of differing severity.
Herein we report deaths in children with MSD (overall,
dysenteric, and non-dysenteric) during 4 years of
enrolment; deaths in children with MSD and LSD and in
their matched controls during the two parallel GEMS-1A
case-control studies; specific pathogens associated with
fatal outcomes; deaths in cases and controls over time
post-enrolment; and insights from verbal autopsies on
potential causes of delayed diarrhoea-associated deaths.

Methods

Study design and participants
The 12-month GEMS-1A study of MSD and LSD
used, with minor exceptions,16 the same clinical,13
epidemiological,11,13 microbiological,17 data management,
and analytical methods14 as the 3-year GEMS study of MSD.
www.thelancet.com/lancetgh Vol 8 February 2020

Six of the original seven GEMS field sites, located in
countries with moderate-to-high mortality of children
younger than 5 years in Africa (Mali, Mozambique,
The Gambia) and Asia (Bangladesh, India, Pakistan)
participated in the GEMS-1A study; cases of MSD only
were enrolled in Kenya during GEMS-1A. Each site
performed a population census and maintained a
demographic surveillance system (DSS) during the casecontrol study to estimate the median population in each
age stratum.12,13,16 For case enrolment, sentinel health
centres were selected where children included in the
DSS sought care for diarrhoeal illnesses, as determined
by Healthcare Utilization and Attitudes Surveys.18
Children aged 0–59 months belonging to the DSS
population at each site who sought care at a sentinel
health centre were screened for diarrhoea, defined as
three or more loose stools during the previous 24 h. Each
child with diarrhoea was assessed for eligibility. Episodes
eligible for inclusion had to be new (onset after
≥7 diarrhoea-free days), acute (onset within the previous
7 days), and fulfil at least one of the following criteria for
MSD: sunken eyes (confirmed by parent or caretaker as
beyond normal); loss of skin turgor; intravenous hydration
administered or prescribed; dysentery (visible blood in
loose stools); or admission to hospital. The remaining
non-MSD, new, acute diarrhoea episodes were eligible to
be enrolled as LSD.16 To maintain a manageable work flow
we enrolled the first eight or nine eligible children with
MSD and LSD per age stratum per fortnight. Following a
prespecified algorithm, we aimed to enrol one to three
control children without diarrhoea for each enrolled MSD
or LSD case, depending on how many cases were enrolled
in a fortnight in a particular age-sex stratum at a study
site;12 in six instances four controls were enrolled.
Controls, matched to each individual case by age
(±2 months for cases aged 0–11 months and ±4 months for
cases aged 12–59 months), sex, and residence (same or
nearby village or neighbourhood as the case) were
randomly selected from the site’s DSS database and
enrolled within 14 days of the case. Potential controls who
had diarrhoea in the preceding 7 days were ineligible.
Enrolment at GEMS sites began on Dec 1 (India), Dec 2
(Bangladesh), Dec 10 (The Gambia, Mozambique), and
Dec 17 (Mali), 2007, Jan 31, 2008 (Kenya), and
March 3, 2008 (Pakistan), and ended on March 3, 2011.
GEMS-1A enrolment began on Oct 31, 2011, and ceased
on Nov 14, 2012.
The clinical protocols for the GEMS and GEMS1-A
studies were approved by ethics committees at the
University of Maryland (Baltimore, MD, USA), and at
every field site. Written informed consent was obtained
from the parent or primary caretaker of each participant.
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Procedures
Study procedures for the GEMS and GEMS1-A studies
have been described in detail elsewhere.11–13,16,17 Entero
pathogens were identified in stool specimens collected
e206
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A
596 519 visits by children aged
0–59 months to sentinel
health centres in 7 sites
(including Kenya)

542 875 visits by children aged
0–59 months to sentinel
health centres in 6 sites
(excluding Kenya)

61 545 with diarrhoea
(10·3% of visits)

59 161 with diarrhoea
(10·9% of visits)

14 753 visits with MSD, 7 sites
(24·0% of diarrhoea visits)

12 679 visits with MSD, 6 sites
(21·4% of diarrhoea visits)

4777 not invited
224 after hours
63 no rectal swab
1928 inadequate stool
2207 quota filled
29 died
66 too sick
260 other

9976 children with MSD invited
(67·6% of MSD visits)

4310 not invited
216 after hours
60 no rectal swab
1804 inadequate stool
1971 quota filled
29 died
40 too sick
190 other

8369 children with MSD invited
(66·0% of MSD visits)

541 refused to enrol

410 refused to enrol

13 128 matched controls

9439 children with MSD enrolled
(94·6% of MSD visits)

7963 children with MSD enrolled
(95·1% of MSD visits)

11 245 matched controls

12 833 had 60-day follow-up

8952 had 60-day follow-up

7173 had 60-day follow-up

10 548 had 60-day follow-up

37 children died

190 children died

138 children died

26 children died

(Figure 1 continues on next page)

See Online for appendix
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at baseline from cases and controls.16,17 Approximately
50 pathogens were detected using, as appropriate, classic
bacteriology, immunoassays, gel-based PCR and reverse
transcriptase PCR, and quantitative real-time PCR
(qPCR).16,17 The laboratory assays used are summarised in
the clinical protocol (appendix pp 1–49). The GEMS-1A
PCR methods for detecting E coli pathotypes are included
in the appendix (pp 50–53). Specimens from a subset of
GEMS cases and controls were also tested using a
TaqMan Array Card that compartmentalised probe-based
qPCR assays for 32 enteropathogens.19
Field workers made a single follow-up visit to
households of cases and controls about 60 days after
enrolment (window 50–90 days) to assess the child’s
vital status, capture interim medical events, and repeat
anthropometric measurements.13,16 Strictly speaking,
deaths in cases during the 60-day follow-up period
constitute an extended case fatality risk,20 while deaths in
controls during the 60-day period constitute a mortality
risk. For simplicity, we use the term risk of death for
both cases and controls.12

When deaths in enrolled children were detected, a time
was arranged (respecting mourning practices) to perform
a verbal autopsy using a WHO questionnaire.13 For deaths
occurring in health centres or hospitals, study-specific
case report form data were collected to complement
information gathered via verbal autopsy. Verbal autopsy
data were reviewed as follows: after standardised training
was done for all sites by the same person (QB), two local
clinicians experienced in verbal autopsy and in
international coding of causes of death independently
reviewed the verbal autopsy forms and assigned up to two
plausible causes of death, using the simplified coding
system based on the International Classification of
Diseases, 10th revision (ICD-10) recommended for verbal
autopsy. If codes assigned by the two reviewers differed, a
third clinician experienced in verbal autopsy served as
arbiter to provide a definitive cause of death code.

Statistical analysis
Sample size considerations and justifications have been
described elsewhere.12 Cumulative risk of death was
www.thelancet.com/lancetgh Vol 8 February 2020
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B
144 225 child-years of observation

192 086 visits by children aged 0–59 months to sentinel
health centres in 6 sites (excluding Kenya)

15 918 with diarrhoea (8·3% of visits)

3718 visits with MSD
(23·4% of diarrhoea visits)

11 225 visits with LSD
(70·5% of diarrhoea visits)

1209 not invited
148 after hours
11 no rectal swab
552 inadequate stool
268 quota filled
4 died
22 too sick
204 other

2509 children with MSD invited
(67·5% of MSD visits)

6977 not invited
656 after hours
17 no rectal swab
2537 inadequate stool
1819 quota filled
1 died
1 too sick
1946 other

4248 children with LSD invited
(37·8% of LSD visits)

141 refused to enrol

1074 refused to enrol

3597 matched controls

2368 children with MSD enrolled
(63·7% of MSD visits)

3174 children with LSD enrolled
(28·3% of LSD visits)

4236 matched controls

3433 had 60-day follow-up

2212 had 60-day follow-up

2692 had 60-day follow-up

4074 had 60-day follow-up

3 children died

23 children died

12 children died

7 children died

(Figure 1 continues on next page)

calculated by the Kaplan-Meier method. Between-group
comparisons of risk of death used proportional hazards
(Cox) regression; when unfeasible because of small
numbers, simple risk ratios were estimated. When cases
and their matched controls were compared, the analysis
was stratified by case-control set.
Cumulative hazard curves from Kaplan-Meier risk of
death analysis are shown for MSD cases during 4 years of
enrolment. Pathogens associated with increased risk of
death in MSD and LSD cases were identified using
multiple Cox regression. Pathogens were included if
there were at least five deaths that tested positive for the
pathogen and if that pathogen was significantly (p<0·10)
associated with death in crude analyses that controlled
only for site. Pathogens were then eliminated from a
model that adjusted for other pathogens until only those
pathogens significantly (p≤0·05) associated with death
remained. This model selection method was used in
GEMS analyses.12,14 Hazard ratios (HRs) and 95% CIs are
presented for all pathogens considered in the crude and
www.thelancet.com/lancetgh Vol 8 February 2020

the final model. Baseline height-for-age or length-for-age
(HAZ) scores at the Pakistan site versus other Asian
sites were compared by two-sample t test. Pair-wise
comparisons were two-sided; results with p values
of 0·05 or lower were considered significant. We made
no imputation of missing values or adjustment for
multiple comparisons. SAS version 9.4 was used for all
analyses apart from Kaplan-Meier cumulative hazard
curves, which were estimated using R version 3.5.3.

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had
full access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results
Figure 1 shows the numbers of enrolled cases and
controls, the number of households that had a follow-up
e208
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C
23 231 child-years of observation

13 399 visits by children aged
0–59 months to sentinel
health centres in Kenya

730 with diarrhoea (5·4% of
visits)

443 visits with MSD (60·7% of
diarrhoea visits)

111 not invited
6 no rectal swab
15 inadequate stool
25 quota filled
7 too sick
58 other

332 with MSD invited (74·9% of
MSD visits)

30 refused to enrol

302 children with MSD enrolled
(91·0% of MSD visits)

565 matched controls

299 had 60-day follow-up

547 had 60-day follow-up

10 children died

3 children died

Figure 1: Study profiles for the GEMS and GEMS-1A studies
(A) GEMS study enrolment of children aged 0–59 months with MSD and matched
controls during 3 years at sentinel health centres at all seven GEMS sites (including
Kenya) and at six sites (excluding Kenya). (B) GEMS-1A study enrolment of children
aged 0–59 months during 1 year when cases of MSD, cases of LSD, and matched
controls were enrolled at sentinel health centres at six sites (excluding Kenya).
(C) GEMS-1A study enrolment of children aged 0–59 months with MSD and
matched controls during 1 year at sentinel health centres at the Kenya site (LSD
cases were not enrolled). MSD=moderate-to-severe diarrhoea. LSD=less-severe
diarrhoea.

visit at about 60 days after enrolment, and deaths in all
age strata combined for the GEMS study, GEMS-1A
study, and Kenya during the GEMS-1A study where only
MSD cases were enrolled. This information is displayed
by age stratum in the appendix (pp 54–56).
Table 1 and figure 2 show the cumulative hazard of
death for all MSD cases, non-dysenteric MSD cases, and
dysenteric MSD cases, and their controls, during the
60-day post-enrolment period for all seven sites during
4 years of enrolment. All MSD cases and the MSD case
subsets (dysentery or non-dysentery) show a significantly
higher risk of death than their controls. Children with
non-dysenteric MSD had a substantially higher risk of
death (2·41 per 100 cases) than did children with dysenteric
e209

MSD (0·84 per 100 cases; p<0·0001). Table 1 also shows
MSD deaths and risk of death by age stratum, with the
heaviest burden in children younger than 24 months.
Of the 223 deaths in children with MSD, 110 (49·3%)
occurred at least 14 days after enrolment and 79 (35·4%)
occurred at least 21 days after enrolment. 193 (86·5%) of
223 deaths in children with MSD and 40 (93·0%) of
43 deaths in control children occurred in the four African
sites. Risk of death estimates in controls at Asian sites
were smaller than those observed at African sites, with
only one death observed per site in controls during the
4 years. However, in children with MSD, the Pakistan site
showed a unique pattern, with 21 deaths, resulting in a
high HR of 16·00 (95% CI 2·12–120·65; table 1); no other
Asian site had more than seven deaths in children with
MSD. Because access to health care and treatment
regimens were similar at the Asian sites, we hypothesised
that children with MSD in Pakistan might have been
more malnourished and thus at increased risk for a fatal
outcome from MSD. Accordingly, we compared baseline
HAZ scores in the 1594 children in Pakistan versus the
3821 children in India plus Bangladesh. Baseline HAZ in
children in Pakistan (HAZ –2·03, 95% CI –2·10 to –1·95)
was significantly lower than that in the other south Asian
children (HAZ –1·31, –1·35 to –1·27; difference between
means –0·72, 95% CI –0·79 to –0·64, p<0·0001).
In an analysis of data from six sites of the study
(excluding Kenya), children with MSD were more likely
to die than their matched controls during the GEMS
study (HR 8·89, 95% CI 5·55–14·22) and GEMS-1A
study (HR 11·91, 3·50–40·53; both p<0·0001; table 2).
Children with dysenteric MSD at these six sites during
the GEMS-1A study were less likely to die during the
follow-up period than were children with non-dysenteric
MSD (HR 0·20, 95% CI 0·05–0·87, p=0·032), as also
observed during the GEMS study at those six sites
(HR 0·41, 0·25–0·67, p=0·0003).
Risk of death per 100 cases in the GEMS-1A study was
significantly higher in children with MSD than in those
with LSD (HR 2·57, 95% CI 1·28–5·17, p=0·0080;
table 2). Nonetheless, risk of death was greater in
children with LSD than in their matched controls,
although not significantly (HR 2·78, 95% CI 0·95–8·11,
p=0·061). Because LSD excludes clinical dysentery, we
compared the risk of death in children with LSD versus
that in children with non-dysenteric MSD, and found the
risk of death to be significantly lower in children with
LSD (HR 0·29, 0·14–0·59, p=0·0006; table 2).
In Cox regression analysis, in all infants aged
0–11 months with MSD in the GEMS and GEMS-1A
studies combined, typical enteropathogenic E coli
(tEPEC), ST-ETEC, and Aeromonas spp infections were
associated with increased risk of death (table 3), as were
Cryptosporidium, tEPEC, enteroaggregative E coli, and
Entamoeba histolytica infection in toddlers aged
12–23 months; the HR changed only minimally when
controlled for breastfeeding (exclusive [defined as
www.thelancet.com/lancetgh Vol 8 February 2020
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MSD cases and their matched controls

Non-dysenteric MSD cases and their matched
controls

Dysenteric MSD cases and their matched
controls

Cases

Controls

HR (95% CI)

p value

Cases

Controls

HR (95% CI)

p value

Cases

Controls

The Gambia

47/1238
(3·8%)

8/2036
(0·4%)

8·62
(3·82–19·42)

<0·0001

36/897
(4·0%)

8/1449
(0·6%)

6·20
(2·68–14·31)

<0·0001

11/341
(3·2%)

0/587

∞

··

Mali

25/2430
(1·0%)

5/2546
(0·2%)

7·67
(2·30–25·53)

<0·0009

22/2116
5/2222
(1·0%)
(0·2%)

6·67
(1·98–22·44)

<0·0022

3/314
(1·0%)

0/324

∞

··

Mozambique

59/725
(8·1%)

13/1550
(0·8%)

10·15
(5·27–19·55)

<0·0001

56/588
(9·5%)

13/1260
(1·0%)

9·60
(4·97–18·56)

<0·0001

3/137
(2·2)

0/290

∞

··

Kenya

62/1718
(3·6%)

14/2388
(0·6%)

6·07
(3·25–11·33)

<0·0001

59/1517
(3·9%)

12/2087
(0·6%)

7·05
(3·59–13·85)

<0·0001

3/201
(1·5%)

2/301
(0·7%)

India

2/2023
(0·1%)

1/2522
(<0·1%)

2·49*
(0·33–19·02)

1·000

2/1764
1/2167
(0·1%)
(<0·1%)

2·46*
(0·32–18·74)

1·000

0/259

0/355

Bangladesh

7/1691
(0·4%)

1/3153
(<0·1%)

11·25
(1·37–92·40)

0·024

6/400
(1·5%)

0/760

1/1291
(0·1%)

1/2393
(<0·1%)

Pakistan

21/1283
(1·6%)

1/2174
(<0·1%)

16·00
(2·12–120·65)

0·0071

18/982
(1·8%)

1/1595
(0·1%)

3/301
(1·0%)

0/579

All sites, age 0–59 months

223†/11 108 43/16 369
8·16
(2·0%)
(0·3%)
(5·69–11·68)

<0·0001

All sites, age 0–11 months

125/4621
(2·7%)

27/5978
(0·5%)

6·42
(4·10–10·06)

<0·0001

··

··

··

··

··

··

··

··

All sites, age 12–23 months

70/3768
(1·9%)

13/5484
(0·2%)

9·54
(4·87–18·70)

<0·0001

··

··

··

··

··

··

··

··

All sites, age 24–59 months

28/2719
(1·0%)

3/4907
(0·1%)

22·47
(5·29–95·41)

<0·0001

··

··

··

··

··

··

··

··

∞

··

13·0
(1·70–99·35)

0·0134

199/8264 40/11 540
7·95
(2·4%)
(0·3%)
(5·46–11·59)

<0·0001

24/2844 3/4829
(0·8%)
(0·1%)

HR (95% CI)

1·19
(0·16–8·61)
∞

p value

0·087
··

1·85*
(0·20–17·74)
∞

··
··

10·38
(3·08–34·96)

0·0002

Data are number of deaths/total (%), unless otherwise stated. Also shown are the distributions of deaths in cases of MSD and deaths in controls by age stratum. MSD=moderate-to-severe diarrhoea. HR=hazard
ratio. *Because of the small number of deaths, for these analyses a simple risk ratio was estimated by a likelihood score method rather than HR by Cox regression. †The 223 total deaths in children with MSD
includes 97 (43·5%) girls and 126 (56·5%) boys, paralleling the enrolment distribution by sex of MSD cases (5280 [43·6%] girls, 6829 [56·4%] boys).

Table 1: Deaths among all MSD cases and non-dysenteric and dysenteric subgroups, and their matched controls, by site in both GEMS and GEMS-1A during 4 years of enrolment

ingesting only breastmilk] vs non-exclusive; see appendix
p 57 for HRs when controlled for breastfeeding). Deaths
in infants with tEPEC were clustered within the first
3 months of life. In infants younger than 3 months who
were not exclusively breastfed, the tEPEC isolation rate
was twice as high (27 [17·2%] of 157) as it was in those
who were exclusively breastfed (16 [7·1%] of 227; odds
ratio 2·74, 95% CI 1·42–5·28; χ² p=0·0026).
Evidence of higher risk of death in children with nondysenteric MSD than in those with dysenteric MSD
(tables 1 and 2), recognition that culture alone may miss
Shigella spp infections detectable by qPCR, and qPCR
data from a large random subset of cases from the GEMS
study19 led us to analyse those data, including qPCR
results for 153 (91·1%) of the 168 children with nondysenteric MSD who died in the GEMS study.
Among 61 deaths in children aged 12–59 months who
had non-dysenteric MSD, 31 occurred in 942 children who
were Shigella-positive by qPCR and 30 deaths occurred in
1384 children qPCR-negative for Shigella spp (HR 2·2,
95% CI 1·2–3·9, p=0·0090 by Cox regression analysis).
Thus, Shigella in children with non-dysenteric MSD was
strongly associated with an increased risk of death.
Notably, only eight (25·8%) of these 31 fatal infections
positive for Shigella spp by qPCR were also positive by
culture, while 23 (74·2%) were culture negative.
Altogether, 285 deaths occurred among cases or controls
in the GEMS study (190 cases, 37 controls) and GEMS-1A
www.thelancet.com/lancetgh Vol 8 February 2020

study (45 cases, 13 controls), and verbal autopsy data were
available for 266 (93·3%; table 4). Because verbal autopsy
interpretation allowed death to have up to two co-primary
diagnoses, total percentages exceeded 100%. Of 230 deaths
with verbal autopsy results, 114 (49·6%) were attributed
to diarrhoeal disease, 26 (11·3%) to sepsis, 19 (8·3%) to
pneumonia or respiratory infections, and 21 (9·1%) to
severe malnutrition. Most deaths could be categorised
either as directly attributable to diarrhoeal disease or
related to sequelae of diarrhoea, including malnutrition
and increased risk of secondary bacterial infections.

Discussion
A hallmark observation from the GEMS study was that
children with MSD had an 8·5 times higher likelihood of
a fatal outcome during the approximately 60-day followup period compared with control children without
diarrhoea.12 This finding has now been corroborated by
data from the GEMS-1A study (12 times increased risk of
death in children with MSD vs matched controls).
In the combined MSD dataset from the GEMS and
GEMS-1A studies, approximately half of MSD-associated
deaths occurred following discharge from the enrolment
sentinel health centre and more than 2 weeks after
enrolment, and would not have been detected had there
not been the systematic single follow-up visit to the
household at about 60 days after enrolment. These
observations imply that within the reference population,
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A
0·05

All MSD cases
Controls

Cumulative hazard

HR (95% CI)

p value

138†/7178 (1·9%)

8·89
(5·55–14·22)

<0·0001

GEMS MSD study

0·04

Cases

0·03

Controls

26†/10 548 (0·3%)

Dysenteric cases

0·01

Non-dysenteric cases

19†/1952 (1·0%)

0

7

14

21

28

35

42

49

56

63

70

77

84

Cases

827
865

Controls

223
43

Cases

119†/5226 (2·3%)
23/2212 (1·0%)

Cumulative hazard

1 (ref)
11·91
(3·50–40·53)

3/3433 (0·1%)
12‡/2962 (0·4%)

··
<0·0001

1 (ref)

··

2·78
(0·95–8·11)

7/4074 (0·2%)

0·061

1 (ref)

··

GEMS-1A MSD study

Non-dysenteric MSD cases
Controls

Dysenteric cases

2/691 (0·3%)

0·04

Non-dysenteric cases

0·20
(0·05–0·87)

21/1521 (1·4%)

0·032

1 (ref)

0·03

Intra-GEMS-1A comparison of MSD versus LSD
GEMS-1A MSD study
cases

23/2212 (1·0%)

0·02

GEMS-1A LSD study
cases

12‡/2962 (0·4%)

0·01

2·57
(1·28–5·17)

··
0·0080

1 (ref)

··

Intra-GEMS-1A comparison of LSD versus non-dysenteric MSD
0

7

14

21

28

35

42

49

56

63

70

Number at risk
Non-dysenteric cases 8213 8155 8118 8087 8077 8065 8041 8025 7278 3846 1768
Controls 11 481 11 478 11 471 11 464 11 461 11 457 11 451 11 421 10 216 4817 2138
Cumulative deaths
Non-dysenteric cases
5
68
99
129 138
150
170 180
189 192 197
Controls
1
4
12
19
21
24
27
31
36
37
37

84

GEMS-1A LSD study
cases

12‡/2962 (0·4%)

77
955
1112

441
435

GEMS-1A MSD study
non-dysenteric cases

21/1521 (1·4%)

198
40

199
40

C
0·05

Dysenteric MSD cases
Controls

0·04
Cumulative hazard

0·0003

GEMS-1A LSD study

Controls

B
0·05

0·29
(0·14–0·59)
1 (ref)

0·0006
··

HR=hazard ratio. MSD=moderate-to-severe diarrhoea. LSD=less-severe diarrhoea.
*The number of participants with follow-up information and therefore for whom
health status (deceased or not) was known. †These numbers exclude GEMS MSD
data from Kenya. ‡The 12 deaths in children with LSD include five (41·6%) girls
and seven (58·3%) boys, paralleling the sex distribution of enrolled LSD cases
(1492 [47·0%] girls, 1682 [53·0%] boys).

Table 2: Risk of death during 60 days of follow-up at six sites (The Gambia,
Mali, Mozambique, India, Bangladesh, and Pakistan)

0·03
0·02
0·01
0

0

7

14

21

28

35

42

49

56

63

70

77

84

808
1226

386
430

24
3

24
3

Time (days)

Number at risk
Dysenteric MSD cases 2829 2822 2815 2814 2813 2812 2808 2804 2657 1845 1168
Controls 4819 4819 4819 4818 4818 4816 4816 4810 4490 2894 1836
Cumulative deaths
Dysenteric MSD cases
0
7
15
16
17
17
21
23
23
24
24
Controls
0
0
0
1
1
2
2
3
3
3
3

Figure 2: Cumulative hazard of death curves
Shaded areas represent 95% CIs. Cumulative hazard of death curves, number at risk, and cumulative deaths
comparing all MSD cases compared with controls (A), non-dysenteric MSD cases compared with controls (B), and
dysenteric MSD cases compared with controls (C) during the approximately 60-day follow-up period
(range 50–90 days) for the seven GEMS and GEMS-1A sites, during 4 years of enrolment. Data are for children who
had a follow-up visit within the 50–90-day window for the day-60 follow-up visit and for whom there was
information about whether or not they had died. MSD=moderate-to-severe diarrhoea.
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0·41
(0·25–0·67)

GEMS-1A MSD study

Number at risk
All MSD cases 11 042 10 977 10 933 10 901 10 890 10 877 10 849 10 829 9935 5691 2936 1763
Controls 16 300 16 297 16 290 16 282 16 279 16 273 16 267 16 231 14 706 7711 3974 2338
Cumulative deaths
All MSD cases
5
75
114
145
155 167
191 203
212 216
221
222
Controls
1
4
12
20
22
26
29
34
39
40
40
43

0

··

1 (ref)

GEMS MSD study

0·02

0

Number of deaths/
total* (%)

the burden of MSD-related deaths far exceeds deaths
detected within the first days of onset of MSD episodes
as observed in sentinel health centres.
Children with MSD in the GEMS-1A study had a
significantly higher risk of death during the 60-day followup period than did children with LSD, an observation that
answers unequivocally the query about whether the
GEMS definition of MSD truly encompasses illnesses
with a greater likelihood of fatal outcome than LSD for
the individual child.21 Nonetheless, findings from the
GEMS-1A study also show that the risk of death in children
with LSD is approximately 2·8 times higher than in
controls without diarrhoea. A larger study with greater
statistical power might have shown LSD to be significantly
associated with risk of death. Consequently, for a similar
number of deaths to accrue among LSD cases as among
MSD cases, it would take approximately 2·5 times the
www.thelancet.com/lancetgh Vol 8 February 2020
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Number of deaths with
Number of deaths with
pathogen present/total (%) pathogen absent/total (%)

HR (95% CI)

p value

Typical EPEC

29/431 (6·7%)

96/4190 (2·3%)

2·58 (1·69–3·93)

<0·0001

ST/LT ETEC and ST-only ETEC

15/290 (5·2%)

110/4331 (2·5%)

1·92 (1·12–3·32)

0·019

6/251 (2·4%)

119/4371 (2·7%)

3·28 (1·27–8·51)

0·015

20/418 (4·8%)

50/3344 (1·5%)

2·14 (1·26–3·65)

0·0050

9/266 (3·4%)

61/3502 (1·7%)

2·35 (1·15–4·81)

0·019

19/645 (2·9%)

51/3123 (1·6%)

2·14 (1·24–3·70)

0·0063

5/114 (4·4%)

65/3648 (1·8%)

3·46 (1·24–9·64)

0·018

0–11 months

Aeromonas spp
12–23 months
Cryptosporidium spp
Typical EPEC
Enteroaggregative Escherichia coli
Entamoeba histolytica

Data include all 4 years of enrolment at seven sites during GEMS and GEMS-1A. MSD=moderate-to-severe diarrhoea. EPEC=enteropathogenic Escherichia coli. ST/LT
ETEC=enterotoxigenic E coli encoding heat-stable toxin with co-expression of heat-labile enterotoxin. ST-only ETEC=enterotoxigenic E coli encoding heat-stable toxin
without co-expression of heat-labile enterotoxin.

Table 3: Specific pathogens associated with a higher risk of fatal outcomes in infants and toddlers with MSD during GEMS and GEMS-1A, by age group

The Gambia

Mali

Mozambique

Kenya

India

Bangladesh

Pakistan

Total

Number of deaths
GEMS deaths cases

39

23

51

52

2

7

16

GEMS deaths controls

7

5

11

11

1

1

1

37

GEMS-1A deaths cases

11

3

11

10

0

2

8

45

GEMS-1A deaths controls

190

3

1

3

3

1

1

1

13

Total deaths in study

60

32

76

76

4

11

26

285

Total deaths with verbal autopsy re-reviewed results

58

31

11

20

266

Discrepancies between physicians

76

66

4

8/58 (13·8%)

5/31 (16·1%)

20/76 (26·3%)

10/66 (15·2%)

0/4

0/11

7/20 (35·0%)

50/266 (18·8%)
114/230 (49·6%)

Causes of death*
Diarrhoeal diseases (A09)

29/50 (58·0%)

15/26 (57·7%)

28/63 (44·4%)

22/55 (40·0%)

2/2 (100%)

8/9 (88·9%)

10/25 (40·0%)

Acute respiratory infection, including pneumonia (J18)

4/50 (8·0%)

6/26 (23·1%)

4/63 (6·3%)

1/55 (1·8%)

1/2 (50·0%)

1/9 (11·1%)

3/25 (12·0%)

19/230 (8·3%)

HIV/AIDS-related death (B24)

0/50

1/26 (3·8%)

20/63 (31·7%)

21/55 38·2%)

0/2

0/9

0/25

42/230 (18·3%)

Severe malnutrition (E46)

14/50 (28·0%)

2/26 (7·7%)

2/63 (3·2%)

2/55 (3·6%)

1/2 (50·0%)

0/9

0/25

21/230 (9·1%)

Sepsis (including neonatal) (A41 and P36)

8/50 (16·0%)

4/26 (15·4%)

6/63 (9·5%)

0/55

0/2

5/9 (55·6%)

3/25 (12·0%)

26/230 (11·3%)

Malaria (B54)

3/50 (6·0%)

4/26 (15·4%)

2/63 (3·2%)

0/2

0/9

1/25 (4·0%)

22/230 (9·6%)

12/55 (21·8%)

*Causes of death (according to verbal autopsy) as primary or co-primary diagnosis (ICD-10 codes) in GEMS and GEMS-1A moderate-to-severe or less-severe diarrhoea cases only. Each patient may have up to
two different diagnoses; therefore, numbers may exceed 100%.

Table 4: Results of the verbal autopsy re-examination exercise

number of LSD cases. Because the number of children
with LSD attending sentinel health centres in the GEMS1A study was around three times the number of children
with MSD, this implies that in the reference population
more deaths overall occur in children with LSD.
Higher numbers of deaths occurred among controls
in African sites than in Asian sites, reflecting the
higher risk of death in children younger than 5 years in
sub-Saharan Africa. Yet the highest risk of death in
children with MSD was in Pakistan. In view of similar
access to care and treatment regimens for MSD at all
three Asian sites, we explored whether host nutritional
differences (baseline nutritional state) might have
contributed to the high risk of death in children with
MSD in Pakistan. Indeed, children with MSD in Pakistan
had significantly more linear growth faltering at baseline
than did children with MSD in India and Bangladesh.
www.thelancet.com/lancetgh Vol 8 February 2020

Several pathogens associated with increasing the
risk of death from MSD in the GEMS study (ST-ETEC,
tEPEC, and Cryptosporidium spp) were similarly identi
fied in the GEMS-1A study, making these robust
observations over multiple years of surveillance. ST-ETEC
can rapidly dehydrate young infants leading to death,
unless effective rehydration is promptly instituted.
tEPEC and Cryptosporidium spp induce similar attaching
and effacing histopathological lesions in small intestinal
mucosa characterised by intimate adherence to entero
cytes, effaced microvilli, and actin polymerisation;22–24
gut dysfunction associated with these intestinal lesions
might increase risk of death.20 Infants with tEPEC
who died showed classic risk factors associated
with severe and fatal disease (ie, early infancy and
lack of exclusive breastfeeding).25 Other pathogens
identified as increasing risk of death were Aeromonas
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spp (infants) and E histolytica and enteroaggregative
E coli (toddlers).
At first glance, a higher risk of death in children with
non-dysenteric MSD than in those with dysenteric MSD
might seem incongruous given the mucosal destruction
that occurs with dysentery. However, dysentery (gross
blood in diarrhoeal stools) is a clinical indication for
treatment with anti-Shigella antibiotics, and most patients
with dysenteric MSD in the GEMS and GEMS-1A studies
received antibiotics. Thus, we hypothesise that antibiotic
treatment lowered the risk of death from dysenteric MSD
compared with non-dysenteric MSD. We also explored
whether Shigella spp might be incriminated more strongly
if we used molecular diagnostics rather than just culture,
assuming the burden of Shigella spp in children with nondysenteric MSD is likely to be underestimated. In the
GEMS study, we had qPCR data from a large random
subset of cases and controls that allowed us to identify
many Shigella-associated cases that had negative stool
cultures.19 In children aged 12–59 months with nondysenteric MSD in the GEMS study, qPCR positivity for
Shigella spp was strongly associated with increased risk
of a fatal outcome. These data reinforce the need for
Shigella vaccines and for an affordable, sensitive, and
specific point-of-care test to diagnose Shigella spp in
patients with non-dysenteric MSD to allow targeted,
rational antibiotic treatment.
Because the occurrence of delayed (≥14 days postenrolment) MSD-associated deaths observed in the
GEMS study has been substantiated by findings in the
GEMS-1A study and an increased risk of death (albeit
lower) has been observed in children with LSD, we must
ponder what is responsible for the deaths. Causal
pathways that could plausibly culminate in delayed
fatality include (1) dehydration worsening or recurring
after discharge from the sentinel health centre, inadequate
oral rehydration at home, and failure to return the child
promptly to health care; (2) bacteraemia secondary to
mucosal injury triggering over-stimulation of the systemic
innate immune system leading to systemic inflammatory
response syndrome (also known as sepsis syndrome);26
(3) gut microbiome alterations consequent to MSD and
LSD allowing translocation and bloodstream invasion by
opportunistic bacterial pathogens even if the intestinal
mucosa remains intact, whereupon clinical sepsis can
ensue; (4) severe gut dysfunction resulting in mal
absorption and anorexia, leading to malnutrition,
micronutrient deficiency and, ultimately, death; (5) rarely,
progression to persistent diarrhoea, a harbinger for fatal
outcomes;27 and (6) an increased risk of pneumonia or
other severe infections following diarrhoeal disease.28
Analysis of verbal autopsy data from children who died
in the African and Asian sites of the GEMS study shows
that the most attributed causes of death coincide with the
above possibilities, even if information for the Asian
sites is limited because of the scarcer number of deaths
occurring there. Nevertheless, verbal autopsy, while
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valuable, is an imperfect tool for interpreting the cause of
death at the individual level. More definitive investigative
tools are needed.29 Underlying HIV-1 infection, malaria,
or severe malnutrition might render children more
susceptible to fatality following MSD or LSD, whatever
the aetiological agent responsible for their diarrhoea. It is
hoped that the evidence of delayed deaths following
MSD and LSD will stimulate innovative clinical and
epidemiological investigations to elucidate the major
precipitating causes of death, so that interventions can be
designed and evaluated.
One limitation of the GEMS and GEMS-1A studies
is that although rotavirus was documented as the
predominant pathogen responsible for MSD and LSD
morbidity, because enrolment was done at sentinel
health centres in which effective rehydration therapy was
available to replace water and electrolyte deficits, deaths
from rotavirus dehydration were uncommon. However,
without access to health care, many infants or toddlers
with rotavirus diarrhoeal dehydration would surely have
died. Rotavirus aside, for groups estimating global
diarrhoeal disease mortality by aetiology,8 the data from
the GEMS and GEMS-1A studies reported here allow
for improved disaggregation by severity, and direct
estimation of population-based (vs hospital-based) risk of
death due to MSD and LSD.8
The risk of death analyses in this study can help public
health decision makers choose what invest
ments to
make among competing priorities. Our data emphasise
the value of preventing or treating all diarrhoeal syndromes
that bring children to health care, including LSD and
MSD. Because the major attributable enteric pathogens
associated with LSD and MSD are the same,12,16 a public
health argument can be made to avert the cascade of
adverse events that follow MSD and LSD by primary
prevention of illnesses caused by certain major attributed
pathogens. One action would be to facilitate future
implementation of vaccines against Shigella spp and ETEC
that are currently in clinical development. Because
vaccines against Cryptosporidium spp remain a distant
goal,30 alternative strategies must diminish the ravages of
that pathogen. One strategy would be to develop affordable
point-of-care diagnostics to detect children infected with
Cryptosporidium spp and safe, effective therapeutics to treat
their infections. Collectively, such interventions can help to
assure that by 2030 diarrhoeal disease will no longer be a
major cause of death in children younger than 5 years in
any resource-scarce, impoverished setting.7
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